Gerresheimer AG/€GXI
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Gerresheimer AG
Gerresheimer AG is a prominent player in the healthcare and life sciences industry, specializing in the production of glass and plastic products for pharmaceutical and cosmetic packaging. The company’s key offerings include pharmaceutical vials, prefillable syringes, glass and plastic packaging for drugs, as well as delivery systems for the safe administration of medications. Founded in 1864, Gerresheimer has evolved into a global entity with headquarters in Düsseldorf, Germany, and operates manufacturing sites in Europe, the Americas, and Asia. Its strategic strength lies in a broad product portfolio and advanced technical expertise, enabling it to cater to the stringent requirements of its diverse clientele in the healthcare sector. The company’s comprehensive geographic footprint and commitment to innovation bolster its competitive position in the market.
Ticker
€GXI
Sector
Primary listing
XETRA
Industry
Life Sciences Tools and Services
Headquarters
Employees
13,616
ISIN
DE000A0LD6E6
Website
Gerresheimer AG Metrics
BasicAdvanced
€1.6B
25.85
€1.83
0.78
€0.04
0.08%
Price and volume
Market cap
€1.6B
Beta
0.78
52-week high
€107.21
52-week low
€42.48
Average daily volume
178K
Dividend rate
€0.04
Financial strength
Current ratio
1.007
Quick ratio
0.438
Long term debt to equity
116.089
Total debt to equity
158.647
Dividend payout ratio (TTM)
68.25%
Interest coverage (TTM)
2.02%
Profitability
EBITDA (TTM)
414.302
Gross margin (TTM)
28.07%
Net profit margin (TTM)
2.89%
Operating margin (TTM)
9.14%
Effective tax rate (TTM)
23.32%
Revenue per employee (TTM)
€160,000
Management effectiveness
Return on assets (TTM)
3.01%
Return on equity (TTM)
4.45%
Valuation
Price to earnings (TTM)
25.848
Price to revenue (TTM)
0.747
Price to book
1.13
Price to tangible book (TTM)
-5.41
Price to free cash flow (TTM)
-3.497
Free cash flow yield (TTM)
-28.59%
Free cash flow per share (TTM)
-1,353.57%
Dividend yield (TTM)
0.08%
Forward dividend yield
0.08%
Growth
Revenue change (TTM)
9.32%
Earnings per share change (TTM)
-45.04%
3-year revenue growth (CAGR)
10.23%
10-year revenue growth (CAGR)
5.22%
3-year earnings per share growth (CAGR)
-11.27%
10-year earnings per share growth (CAGR)
-1.86%
3-year dividend per share growth (CAGR)
-68.25%
10-year dividend per share growth (CAGR)
-25.41%
Bulls say / Bears say
Gerresheimer's strategic focus on containment solutions and drug delivery systems for biologics, including GLP-1 obesity drugs like Wegovy, positions the company to benefit from the growing demand in this sector. (reuters.com)
Despite recent challenges, Gerresheimer's reaffirmation of its 2025 guidance and expectations for stronger performance in the second half of the year indicate potential for recovery and growth. (reuters.com)
The company's acquisition of Bormioli Pharma and the creation of a new molded glass business unit could enhance its market position and product offerings, potentially driving future revenue growth. (reuters.com)
Gerresheimer's recent downgrade of its 2025 revenue and profit margin outlook due to weakened demand in the cosmetics and liquid medications markets raises concerns about its near-term financial performance. (reuters.com)
The company's decision to slash its 2024 dividend from €1.25 to €0.04 per share to preserve financial flexibility may signal underlying financial strains and could deter income-focused investors. (reuters.com)
The withdrawal of KKR from the private equity consortium considering a takeover of Gerresheimer, leading to a significant share price decline, reflects potential investor skepticism about the company's valuation and future prospects. (reuters.com)
Data summarised monthly by Lightyear AI. Last updated on 29 Jun 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Gerresheimer AG stock?
Gerresheimer AG (GXI) has a market cap of €1.6B as of July 18, 2025.
What is the P/E ratio for Gerresheimer AG stock?
The price to earnings (P/E) ratio for Gerresheimer AG (GXI) stock is 25.85 as of July 18, 2025.
Does Gerresheimer AG stock pay dividends?
Yes, the Gerresheimer AG (GXI) stock pays dividends to shareholders. As of July 18, 2025, the dividend rate is €0.04 and the yield is 0.08%. Gerresheimer AG has a payout ratio of 68.25% on a trailing twelve-month basis.
When is the next Gerresheimer AG dividend payment date?
The next Gerresheimer AG (GXI) dividend payment date is unconfirmed.
What is the beta indicator for Gerresheimer AG?
Gerresheimer AG (GXI) has a beta rating of 0.78. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.